NRx Pharmaceuticals (NRXP) Soars As It Announces Progress In The Development Of ZYESAMI

Yesterday, NRx Pharmaceuticals soared 61.06% and traded at $10.92. This week, the company made a big leap. The stock on October 7 was $8.25. On October 11, it fell to $6.58. The next day, the price rose to $9.72. NRX Pharmaceuticals (NBSP), announced yesterday that a research New drug module for the production of ZYESAMI ™ has been submitted to the US Food and Drug Administration (FDA). This document confirms that Nephron Pharmaceuticals is ready to supply ZYESAMI on a commercial scale.

The European auditor QP (Qualified Person) has also informed NRx that the inspection at a separate production facility was conducted without any negative results. NRx is awaiting the QP declaration, which EU regulatory authorities require before issuing ZYESAMI. The audit was done in preparation for the European Union (EU) ZYESAMI standard to be submitted to the EU and UK health regulatory authorities. The QP auditor is responsible for ensuring that each batch of a pharmaceutical product meets all of the relevant requirements when it is discharged from a production facility in the EU or imported into the EU, according to EU legislation.